Objectives: To evaluate the efficacy and tolerability of tolterodine extended release (ER) in men and women with overactive bladder (OAB).

Methods: We analyzed data from two 12-wk, placebo-controlled trials of tolterodine ER (4mg QD). Patients completed 7-d bladder diaries and rated the urgency sensation associated with each micturition on a 5-point urgency rating scale. Micturitions were categorized by urgency rating: total (1-5), non-OAB (1-2), OAB (3-5), or severe OAB (4-5). Changes in micturitions during 24-h, daytime, and nocturnal intervals were assessed.

Results: At baseline, 73% (547 of 745) of men and 57% (539 of 953) of women were continent. By week 12, tolterodine ER (n=848) reduced OAB and severe OAB micturitions during 24-h, daytime, and nocturnal intervals in both sexes compared with placebo (n=850). Adverse event rates were low and similar across treatment and gender.

Conclusions: In men and women with OAB, tolterodine ER reduced OAB and severe OAB micturitions, and was well tolerated.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2006.10.005DOI Listing

Publication Analysis

Top Keywords

severe oab
12
efficacy tolerability
8
tolerability tolterodine
8
tolterodine extended
8
extended release
8
overactive bladder
8
men women
8
urgency rating
8
micturitions 24-h
8
24-h daytime
8

Similar Publications

Objectives: To determine the health utility values (HUVs) of overactive bladder (OAB), defined as urinary urgency, usually accompanied by urinary daytime or nocturnal frequency, with or without urinary incontinence, among adults aged ≥65 years and to assess the HUV decrements (disutilities) of OAB according to its severity.

Methods: This cross-sectional Internet-based study was conducted between 2 and 9 November 2023, with quota sampling with equal probability for each sex and age group (age 65-74 years and ≥75 years). OAB was defined as an urgency score of ≥2 points and a total score of ≥3 points based on the Overactive Bladder Symptom Score.

View Article and Find Full Text PDF

Background: Overactive bladder syndrome (OAB) is a prevalent urological condition which has a substantial impact on the life quality of affected individuals, resulting in restrictions in daily activities and work productivity. Alcohol is a diuretic, which means that it increases urine production and can potentially worsen urinary urgency and frequency. Several studies have investigated the association between alcohol consumption and OAB symptoms, but the results have been conflicting.

View Article and Find Full Text PDF

Background: In male patients, benign prostate hyperplasia (BPH) and overactive bladder (OAB) secondary to BPH are the primary causes of Lower Urinary Tract Symptoms (LUTS). Recent clinical studies have reported an increased risk of LUTS, particularly severe LUTS conditions, in male asthmatic patients. However, the potential link and mechanism remain unclear.

View Article and Find Full Text PDF

Objective: This study aims to investigate the relationship between HPV-associated LSIL and HSIL lesions and overactive bladder (OAB) symptoms in postmenopausal women, highlighting the role of severe histopathological lesions.

Materials And Methods: A retrospective analysis was conducted on postmenopausal women aged 40-65 years who presented at Istanbul Bakırköy Sadi Konuk Training and Research Hospital between January 2021 and March 2023. The study included HPV-positive patients with low-grade squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL), as well as HPV-negative controls.

View Article and Find Full Text PDF

Purpose: Mirabegron, the first-in-class beta-3 agonist, is the mainstay medication for overactive bladder (OAB). The aim of this study was to investigate the efficacy and safety of generic drugs of mirabegron (Mirabek) in adults diagnosed with OAB through a multicenter, prospective, non-interventional observational study.

Materials And Methods: Adult patients with OAB prescribed Mirabek SR Tab.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!